Skip to content

Study · Not a test of the peptide alone · 2020

1 result

Using low-dose tissue plasminogen activator through external ventricular drain and Cerebrolysin for the treatment of severe intraventricular hemorrhage: A case report.

Hoang Ngoc N, Van Tuyen N

SAGE open medical case reports25 Dec 2020

PMID33489233 (opens in a new tab)PMCIDPMC7768572 (opens in a new tab)DOI10.1177/2050313x20981464 (opens in a new tab)PepBankPUB-33489233
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 01HumanNot a test of Cerebrolysin aloneCase report or seriesEfficacy outcome

    In one patient with intraventricular hemorrhage, a multimodal regimen including Cerebrolysin and neurorehabilitation achieved successful treatment.

    In plain wordsIn one patient, treatment with several methods including Cerebrolysin and rehabilitation succeeded.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableClinical treatment success
    Study

    n = 1

    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    successfully treated with a combination of methods: endovascular embolization of arteriovenous malformation, external ventricular drainage, intraventricular fibrinolysis with low-dose recombinant tissue plasminogen activator, and medical treatment with the neurotrophic drug Cerebrolysin in combinati…

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.